Complete Filing Data
Mineralys Therapeutics, Inc. reported Stockholders Equity of $646.69 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Mineralys Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income Loss | -$154.7M | -$177.8M | -$71.9M | -$29.8M |
| Research And Development Expense | $132.0M | $168.6M | $70.4M | $26.3M |
| Operating Income Loss | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Operating Expenses | $170.6M | $192.4M | $84.7M | $31.5M |
| Nonoperating Income Expense | $16.0M | $14.6M | $12.8M | $1.7M |
| Interest Income Expense Nonoperating Net | $16.0M | $14.6M | $12.8M | $1.7M |
| General And Administrative Expense | $38.6M | $23.8M | $14.3M | $5.2M |
| Other Nonoperating Income Expense | $0.00 | $5.0K | $3.0K | |
| Other Nonoperating Income | $3.0K | $4.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$36.9M | -$43.3M | -$42.2M | -$56.3M | -$41.0M | -$31.5M | -$22.8M | -$12.1M | -$12.6M | -$6.7M | -$6.5M | -$7.6M |
| Research And Development Expense | $31.5M | $38.3M | $37.9M | $54.0M | $39.3M | $30.8M | $22.5M | $11.9M | $12.3M | $6.1M | $5.6M | $6.8M |
| Operating Income Loss | -$41.1M | -$46.7M | -$44.4M | -$60.1M | -$45.2M | -$35.4M | -$26.3M | -$15.7M | -$14.9M | -$7.4M | -$6.5M | -$7.6M |
| Operating Expenses | $41.1M | $46.7M | $44.4M | $60.1M | $45.2M | $35.4M | $26.3M | $15.7M | $14.9M | $7.4M | $6.5M | $7.6M |
| Nonoperating Income Expense | $4.2M | $3.5M | $2.2M | $3.8M | $4.2M | $3.9M | $3.5M | $3.6M | $2.3M | $745.0K | $0.00 | $0.00 |
| Interest Income Expense Nonoperating Net | $4.2M | $3.5M | $2.2M | $3.8M | $4.2M | $3.9M | $3.5M | $3.6M | $2.3M | $741.0K | $0.00 | $0.00 |
| General And Administrative Expense | $9.7M | $8.5M | $6.6M | $6.1M | $5.9M | $4.6M | $3.8M | $3.9M | $2.6M | $1.4M | $884.0K | $791.0K |
| Other Nonoperating Income Expense | $4.0K | -$2.0K | -$3.0K | -$10.0K | $2.0K | $1.0K | $0.00 | |||||
| Other Nonoperating Income | $2.0K | $1.0K | $0.00 | $1.0K | $1.0K | $4.0K | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | $646.7M | $191.3M | $241.2M | -$52.3M | -$22.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $172.9M | $114.1M | $49.3M | $87.7M | $10.7M |
| Retained Earnings Accumulated Deficit | -$457.2M | -$302.5M | -$124.7M | -$52.8M | |
| Prepaid Expense And Other Assets Current | $4.8M | $7.2M | $12.5M | $2.7M | |
| Other Assets Noncurrent | $382.0K | $499.0K | $51.0K | $1.6M | |
| Liabilities Current | $15.1M | $14.6M | $10.5M | $8.1M | |
| Liabilities And Stockholders Equity | $661.8M | $205.9M | $251.6M | $114.4M | |
| Common Stock Value | $8.0K | $5.0K | $4.0K | $1.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $58.8M | $64.8M | -$38.4M | $77.0M | |
| Cash And Cash Equivalents At Carrying Value | $172.9M | $114.1M | $49.3M | $87.7M | |
| Assets Current | $661.4M | $205.4M | $249.1M | $112.8M | |
| Assets | $661.8M | $205.9M | $251.6M | $114.4M | |
| Accrued Liabilities Current | $13.1M | $14.2M | $9.9M | $6.2M | |
| Accretion Amortization Of Discounts And Premiums Investments | $9.9M | $9.4M | $6.9M | $649.0K | |
| Accounts Payable Current | $2.0M | $479.0K | $601.0K | $1.9M | |
| Property Plant And Equipment Net | $38.0K | $53.0K | $0.00 | ||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent | $0.00 | ||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current | $22.4M | ||||
| Investments And Cash | $656.6M | $198.2M | $239.0M | ||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss | $22.4M | ||||
| Debt Securities Current | $483.7M | $84.1M | $187.3M | ||
| Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction | $0.00 | $360.0K | |||
| Marketable Securities Noncurrent | $0.00 | $2.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $576.4M | $313.6M | $341.6M | $236.9M | $290.1M | $328.0M | $264.0M | $285.0M | $295.9M | -$43.4M | -$36.9M | -$30.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $217.6M | $101.8M | $165.0M | $97.3M | $67.9M | $90.4M | $86.3M | $101.1M | $138.2M | $49.0M | $128.3M | $16.1M | |
| Retained Earnings Accumulated Deficit | -$424.9M | -$388.0M | -$344.7M | -$253.6M | -$197.2M | -$156.2M | -$100.3M | -$77.6M | -$65.4M | ||||
| Prepaid Expense And Other Assets Current | $6.2M | $10.4M | $11.5M | $4.1M | $6.9M | $8.3M | $11.6M | $8.4M | $4.6M | ||||
| Other Assets Noncurrent | $144.0K | $433.0K | $397.0K | $452.0K | $449.0K | $379.0K | $51.0K | $51.0K | $39.0K | ||||
| Liabilities Current | $23.5M | $22.2M | $13.4M | $31.3M | $28.4M | $19.2M | $13.5M | $6.2M | $10.6M | ||||
| Liabilities And Stockholders Equity | $599.9M | $335.7M | $354.9M | $268.3M | $318.5M | $347.2M | $277.6M | $291.2M | $306.4M | ||||
| Common Stock Value | $8.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $50.9M | $41.1M | $50.5M | $5.4M | |||||||||
| Cash And Cash Equivalents At Carrying Value | $217.6M | $101.8M | $165.0M | $97.3M | $67.9M | $90.4M | $86.3M | $101.1M | $138.2M | ||||
| Assets Current | $599.8M | $335.3M | $354.5M | $267.7M | $318.0M | $346.8M | $265.4M | $269.5M | $275.3M | ||||
| Assets | $599.9M | $335.7M | $354.9M | $268.3M | $318.5M | $347.2M | $277.6M | $291.2M | $306.4M | ||||
| Accrued Liabilities Current | $22.4M | $19.0M | $13.0M | $28.2M | $26.7M | $14.9M | $8.0M | $4.0M | $8.2M | ||||
| Accretion Amortization Of Discounts And Premiums Investments | $1.0M | $2.5M | $855.0K | $0.00 | |||||||||
| Accounts Payable Current | $1.1M | $3.2M | $373.0K | $3.1M | $1.7M | $4.3M | $5.6M | $2.2M | $2.4M | ||||
| Property Plant And Equipment Net | $7.0K | $22.0K | $38.0K | $69.0K | $42.0K | $51.0K | |||||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent | $0.00 | $0.00 | $0.00 | $2.5M | $12.1M | $21.7M | $31.1M | ||||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current | $166.3M | $243.3M | $248.1M | $187.3M | $167.5M | $160.0M | $132.4M | ||||||
| Investments And Cash | $593.6M | $324.9M | $343.0M | $263.6M | $311.1M | $338.6M | $265.9M | $282.8M | $301.8M | ||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss | $166.3M | $243.3M | $248.1M | $189.7M | $179.6M | $181.6M | $163.5M | ||||||
| Debt Securities Current | $376.0M | $223.1M | $178.0M | ||||||||||
| Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction | $581.0K | $0.00 | |||||||||||
| Marketable Securities Noncurrent |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Share Based Compensation | $19.3M | $11.3M | $5.1M | $455.0K |
| Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities | $425.0M | $488.5M | $187.5M | $50.0M |
| Payments To Acquire Held To Maturity Securities | $814.7M | $373.4M | $348.0M | $71.8M |
| Net Cash Provided By Used In Operating Activities | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Net Cash Provided By Used In Investing Activities | -$389.8M | $115.0M | -$160.5M | -$21.8M |
| Net Cash Provided By Used In Financing Activities | $591.0M | $116.1M | $203.2M | $128.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$2.5M | -$4.9M | $9.5M | $2.2M |
| Increase Decrease In Accrued Interest Receivable Net | $166.0K | -$424.0K | $355.0K | $0.00 |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $427.0K | $4.2M | $2.4M | $3.0M |
| Proceeds From Stock Options Exercised | $12.8M | $297.0K | $194.0K | $0.00 |
| Proceeds From Issuance Of Private Placement | $0.00 | $116.1M | $0.00 | |
| Payments To Acquire Productive Assets | $15.0K | $96.0K | $0.00 | |
| Payments Of Stock Issuance Costs | $391.0K | $435.0K | $0.00 | |
| Depreciation Depletion And Amortization | $59.0K | $43.0K | $0.00 | |
| Proceeds From Stock Plans | $243.0K | $221.0K | $64.0K | $0.00 |
| Proceeds From Issuance Initial Public Offering | $0.00 | $203.0M | -$1.6M | |
| Proceeds From Issuance Of Common Stock | ||||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Share Based Compensation | $3.6M | $2.2M | $749.0K | $19.0K |
| Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities | $35.0M | $67.5M | $22.5M | $0.00 |
| Payments To Acquire Held To Maturity Securities | $127.9M | $123.4M | $162.8M | $0.00 |
| Net Cash Provided By Used In Operating Activities | -$45.5M | -$19.1M | -$12.8M | -$6.6M |
| Net Cash Provided By Used In Investing Activities | -$92.9M | -$56.0M | -$140.3M | $0.00 |
| Net Cash Provided By Used In Financing Activities | $189.3M | $116.2M | $203.6M | $12.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $4.4M | -$4.2M | $1.7M | -$108.0K |
| Increase Decrease In Accrued Interest Receivable Net | -$52.0K | -$119.0K | $270.0K | $0.00 |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$1.5M | $8.4M | $1.9M | $864.0K |
| Proceeds From Stock Options Exercised | $123.0K | $149.0K | $0.00 | |
| Proceeds From Issuance Of Private Placement | $0.00 | $116.1M | $0.00 | |
| Payments To Acquire Productive Assets | $0.00 | $59.0K | $0.00 | |
| Payments Of Stock Issuance Costs | $10.0K | $63.0K | $0.00 | |
| Depreciation Depletion And Amortization | $15.0K | $8.0K | $0.00 | |
| Proceeds From Stock Plans | ||||
| Proceeds From Issuance Initial Public Offering | $0.00 | $203.6M | ||
| Proceeds From Issuance Of Common Stock | $189.2M | $0.00 | $203.6M | $0.00 |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock | $0.00 | $12.0M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 67.7M | 48.5M | 36.2M | 5.2M |
| Weighted Average Number Of Diluted Shares Outstanding | 67.7M | 48.5M | 36.2M | 5.2M |
| Earnings Per Share Diluted | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Earnings Per Share Basic | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 319.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 81.5M | 49.8M | 41.1M | 6.4M |
| Common Stock Shares Issued | 81.5M | 49.8M | 41.1M | 6.4M |
| Temporary Equity Shares Authorized | 50.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 70.6M | 65.5M | 53.2M | 49.8M | 49.4M | 44.9M | 39.9M | 39.8M | 24.8M | 5.2M | 5.2M | 5.1M |
| Weighted Average Number Of Diluted Shares Outstanding | 70.6M | 65.5M | 53.2M | 49.8M | 49.4M | 44.9M | 39.9M | 39.8M | 24.8M | 5.2M | 5.2M | 5.1M |
| Earnings Per Share Diluted | $-0.52 | $-0.66 | $-0.79 | $-1.13 | $-0.83 | $-0.70 | $-0.57 | $-0.31 | $-0.51 | $-1.29 | $-1.26 | $-1.48 |
| Earnings Per Share Basic | $-0.52 | $-0.66 | $-0.79 | $-1.13 | $-0.83 | $-0.70 | $-0.57 | $-0.31 | $-0.51 | $-1.29 | $-1.26 | $-1.48 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 79.0M | 65.7M | 64.9M | 49.8M | 49.7M | 49.6M | 41.1M | 40.9M | 40.9M | |||
| Common Stock Shares Issued | 79.0M | 65.7M | 64.9M | 49.8M | 49.7M | 49.6M | 41.1M | 40.9M | 40.9M | |||
| Temporary Equity Shares Authorized | 50.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $19.3M | $11.3M | $5.1M | $455.0K |
| Stock Issued During Period Value Stock Options Exercised | $12.8M | $297.0K | $194.0K | |
| Additional Paid In Capital | $1.10B | $493.8M | $365.9M | $540.0K |
| Stock Issued During Period Value New Issues | $116.1M | $201.4M | ||
| Conversion Of Stock Amount Converted1 | $0.00 | $159.2M | $0.00 | |
| Offering Costs Incurred During Noncash Or Partial Noncash Transaction | $41.0K | $0.00 | ||
| Stock Issued During Period Value Employee Stock Purchase Plan | $243.0K | $221.0K | ||
| Stock Issued During Period Value Conversion Of Convertible Securities | $158.6M | |||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $3.9M | |||
| Stock Issued During Period Value Employee Stock Ownership Plan | $221.0K | $64.0K | ||
| Stock Issued During Period Shares Stock Options Exercised | 1.4M | 321.9K | 268.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.8M | $4.6M | $3.6M | $3.1M | $2.9M | $2.2M | $1.6M | $1.3M | $749.0K | $192.0K | $26.0K | $19.0K |
| Stock Issued During Period Value Stock Options Exercised | $6.6M | $1.1M | $123.0K | $40.0K | $54.0K | $149.0K | $184.0K | |||||
| Additional Paid In Capital | $1.00B | $701.5M | $686.3M | $490.5M | $487.3M | $484.3M | $364.3M | $362.6M | $361.3M | |||
| Stock Issued During Period Value New Issues | $9.5M | $188.7M | $116.1M | $201.4M | ||||||||
| Conversion Of Stock Amount Converted1 | $0.00 | $159.2M | $0.00 | |||||||||
| Offering Costs Incurred During Noncash Or Partial Noncash Transaction | $289.0K | $321.0K | $581.0K | |||||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $142.0K | $138.0K | ||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $158.6M | |||||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $46.0K | $12.5M | $3.9M | |||||||||
| Stock Issued During Period Value Employee Stock Ownership Plan | ||||||||||||
| Stock Issued During Period Shares Stock Options Exercised |
Most recent annual filing with the SEC: March 12, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.